Appointment of John Hohneker,
M.D.
Resignation of Chidozie Ugwumba
PHILADELPHIA, April 1,
2024 /PRNewswire/ -- Carisma Therapeutics
Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a
clinical-stage biopharmaceutical company focused on discovering and
developing innovative immunotherapies, today announced the
appointment of John Hohneker, M.D.
to the Board of Directors of the Company, effective April 1, 2024. Additionally, the Company
announced that Chidozie Ugwumba, who has served on Carisma's
Board of Directors since December
2020, has advised the Board of his intent to step down from
his role as a member of the Board and chair of the Audit Committee
of the Board effective April 1, 2024,
as a result of his other professional commitments.
"We are pleased to welcome John to the Carisma Board of
Directors," said Sanford Zweifach,
Chair of the Carisma Board of Directors. "I believe John's
extensive track record of clinical development, strategic
leadership, and public company Board membership in the
biopharmaceutical space will enable him to immediately support the
Company as it continues leading the field of engineered macrophage
development. We would also like to thank Chidozie for his
invaluable advice and guidance since he first joined the Board over
three years ago."
"I am excited to join Carisma's Board as the Company continues
to develop innovative immunotherapies," said Dr. Hohneker. "I am
looking forward to partnering with the Board and the management
team as they work to potentially bring novel treatments to patients
in need across multiple therapeutic areas."
Dr. Hohneker brings over 30 years of extensive experience in
drug development and leadership across the biotech and
pharmaceutical sectors. He most recently served as President and
Chief Executive Officer of Anokion SA. Prior to this, he held the
role of President of Research and Development at FORMA Therapeutics
Inc. Before joining FORMA Therapeutics, Dr. Hohneker held roles of
increasing responsibility at Novartis AG, including most recently
as Senior Vice President and Global Head of Development,
Immunology, and Dermatology. Prior to his time at Novartis, Dr.
Hohneker held positions of increasing responsibility at Glaxo
Wellcome and its legacy company, Burroughs Wellcome.
Dr. Hohneker currently serves on the Board of Directors of
Curis, Inc., Sonata Therapeutics, Inc., and Trishula Therapeutics,
Inc. Previously, Dr. Hohneker has served as a member of the Board
of Directors of Torque Therapeutics, Inc., Dimension
Therapeutics, Inc., Cygnal Therapeutics, Inc., BioTheryX Inc.,
Evelo Biosciences, Inc., Humanigen, Inc. and Aravive, Inc. Dr.
Hohneker received his bachelor's degree in chemistry from
Gettysburg College and his M.D. from
the Rutgers School of Biomedical and Health Sciences (formerly the
University of Medicine and Dentistry of New
Jersey-Rutgers Medical School). He completed his internship
and residency in internal medicine and his fellowship in medical
oncology, all at the University of North
Carolina at Chapel Hill.
About Carisma
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical
company focused on utilizing our proprietary macrophage and
monocyte cell engineering platform to develop transformative
immunotherapies to treat cancer and other serious diseases. We have
created a comprehensive, differentiated proprietary cell therapy
platform focused on engineered macrophages and monocytes, cells
that play a crucial role in both the innate and adaptive immune
response. Carisma is headquartered in Philadelphia, PA. For more information, please
visit www.carismatx.com.
Investors:
Shveta
Dighe
Head of Investor Relations
investors@carismatx.com
Media Contact:
Julia
Stern
(763) 350-5223
jstern@realchemistry.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-announces-changes-to-its-board-of-directors-302104078.html
SOURCE Carisma Therapeutics Inc.